Steven Pals

Affiliate Professor of Immunopathology and Hematopathology

University of Copenhagen

Denmark

Research Interests

Explore related searches

Professors in Immunology

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Steven Pals is an Affiliate Professor of Immunopathology and Hematopathology at the University of Copenhagen, Denmark. His research focuses on the intricacies of immune responses in hematological malignancies, emphasizing therapeutic targets and signaling pathways in diseases such as mantle cell lymphoma and multiple myeloma. Recent articles authored by Professor Pals explore topics including bispecific antibodies, chemokine mediation in drug resistance, and precision therapy in diffuse large B-cell lymphoma.

Articles (10)

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (4)

Konnie Hebeda

department of pathology erasmus university medical center rotterdam the netherlands

NETHERLANDS

View details

Jeroen E. J. Guikema

Amsterdam University Medical Centers

NETHERLANDS

View details

Hans J. van der Vliet

University of Amsterdam

NETHERLANDS

View details

Eric Eldering

groupleader/professor

Academic Medical Center

NETHERLANDS

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Steven Pals

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

A bispecific antibody antagonizes prosurvival CD40 signaling and promotes Vγ9Vδ2 T cell-mediated antitumor responses in human B-cell malignancies

Correction to: The CXCL12gamma chemokine immobilized by heparan sulfate on stromal niche cells controls adhesion and mediates drug resistance in multiple myeloma (Journal of Hematology & Oncology, (2021), 14, 1, (11), 10.1186/s13045-021-01031-3)

Identification of the SRC-family tyrosine kinase HCK as a therapeutic target in mantle cell lymphoma

Spectrum of histiocytic neoplasms associated with diverse haematological malignancies bearing the same oncogenic mutation

Syndecan-1 and stromal heparan sulfate proteoglycans: key moderators of plasma cell biology and myeloma pathogenesis

The CXCL12gamma chemokine immobilized by heparan sulfate on stromal niche cells controls adhesion and mediates drug resistance in multiple myeloma

AKT signaling restrains tumor suppressive functions of FOXO transcription factors and GSK3 kinase in multiple myeloma

Hepatocyte growth factor/MET and CD44 in colorectal cancer: partners in tumorigenesis and therapy resistance

MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis

Towards genomic-based prognostication and precision therapy for diffuse large B-cell lymphoma

Collaborators (4)

Konnie Hebeda

Jeroen E. J. Guikema

Hans J. van der Vliet

Eric Eldering

Make your next move.

Steven Pals

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

A bispecific antibody antagonizes prosurvival CD40 signaling and promotes Vγ9Vδ2 T cell-mediated antitumor responses in human B-cell malignancies

Correction to: The CXCL12gamma chemokine immobilized by heparan sulfate on stromal niche cells controls adhesion and mediates drug resistance in multiple myeloma (Journal of Hematology &amp; Oncology, (2021), 14, 1, (11), 10.1186/s13045-021-01031-3)

Identification of the SRC-family tyrosine kinase HCK as a therapeutic target in mantle cell lymphoma

Spectrum of histiocytic neoplasms associated with diverse haematological malignancies bearing the same oncogenic mutation

Syndecan-1 and stromal heparan sulfate proteoglycans: key moderators of plasma cell biology and myeloma pathogenesis

The CXCL12gamma chemokine immobilized by heparan sulfate on stromal niche cells controls adhesion and mediates drug resistance in multiple myeloma

AKT signaling restrains tumor suppressive functions of FOXO transcription factors and GSK3 kinase in multiple myeloma

Hepatocyte growth factor/MET and CD44 in colorectal cancer: partners in tumorigenesis and therapy resistance

MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis

Towards genomic-based prognostication and precision therapy for diffuse large B-cell lymphoma

Collaborators (4)

Konnie Hebeda

Jeroen E. J. Guikema

Hans J. van der Vliet

Eric Eldering

Make your next move.

Correction to: The CXCL12gamma chemokine immobilized by heparan sulfate on stromal niche cells controls adhesion and mediates drug resistance in multiple myeloma (Journal of Hematology & Oncology, (2021), 14, 1, (11), 10.1186/s13045-021-01031-3)